A b s t r a c t
Hypovitaminosis D is a relatively common problem traditionally manifesting in the elderly population and in people with severe liver or kidney disease. 1, 2 Vitamin D deficiency has increasingly manifested in the general population due to lack of sun exposure, poor nutritional status, and increased use of sunscreens. 3, 4 Inadequate levels of vitamin D can lead to increased risk of cancer, diabetes mellitus, chronic pain, and hypertension. [5] [6] [7] [8] [9] [10] Vitamin D 2 (ergocalciferol) and D 3 (cholecalciferol) may come from exogenous sources, but only vitamin D 3 is produced in the skin from 7-dehydrocholesterol upon exposure to sunlight. Vitamin D 2 Several methods, including high-performance liquid chromatography (HPLC), chemiluminescence, and radioimmunoassay (RIA) have been developed for measurement of total 25(OH)D levels. Although HPLC techniques with UV detection are capable of determining 25(OH)D 2 and 25(OH)D 3 levels simultaneously, there are significant drawbacks. Most HPLC methods require large sample volumes (0.5-2 mL) and time-consuming procedures before quantification. 11 Suboptimal crossreactivity of the antibody with 25(OH)D 2 
Materials and Methods

Chemicals and Reagents
Absolute ethyl alcohol was purchased from Aaper Alcohol and Chemical (Shelbyville, KY), and ammonium acetate was obtained from ICN Biomedicals (Costa Mesa, CA). HPLC-grade methanol and n-heptane were acquired from J.T. Baker (Phillipsburg, NJ) and Fischer Scientific (Fairlawn, NJ), respectively. 25(OH)D 2 and 25(OH)D 3 were purchased from Sigma-Aldrich (St Louis, MO). These 2 lyophilized powders were diluted with ethanol and used to make working standards (concentrations of each analyte: 1, 30, and 100 ng/mL). Control samples were prepared from pooled serum specimens that were assayed and spiked with vitamin D standards with optimal control values for 25(OH)D 2 and 25(OH)D 3 less than 15 ng/mL (low) and 20 to 40 ng/mL (high). The internal standard, ∆ 9 -THC-D 3 (Cerilliant, Round Rock, TX), was diluted with methanol to a final concentration of 50 ng/mL.
Sample Preparation
For each patient serum specimen and control sample, 200 µL of sample was placed in a glass 13 × 100-mm disposable tube followed by 200 µL of internal standard. The samples were vortex-mixed, extracted with 1 mL of n-heptane, and centrifuged for 4 minutes at 3,000 rpm. The organic layer was removed, evaporated under nitrogen, and reconstituted in 100 µL of ethyl alcohol. After brief vortex mixing, the samples were transferred to labeled auto-sampler vials. Control samples were extracted with patient samples during every run. The standards were assayed unextracted, with 100 µL of standard mixed with 200 µL of internal standard. This solution was vortex-mixed and dried under nitrogen. Standards were reconstituted in ethyl alcohol, and the solutions were transferred into auto-sampler vials. Then, 20 µL of each standard, control sample, or patient specimen was injected into the LC-MS/MS system.
LC-MS/MS Instrumentation and Analysis
The LC-MS/MS system consisted of a Waters Alliance 2795 HPLC interfaced to a Waters Micromass Quattro tandem quadrupole mass spectrometer (Waters, Milford, MA). Chromatographic separation of 25(OH)D 2 , 25(OH)D 3 , and ∆ 9 -THC-D 3 was achieved with a Waters XTerra analytical column (50 × 2.1 mm internal diameter; 3.5-µm particle size; Waters) maintained at a temperature of 35°C. An isocratic mobile phase was used and consisted of 100% methanol with 2 mmol/L of ammonium acetate and 0.1% formic acid. The flow rate was 100 µL/min from 0.0 to 4.0 minutes, at which point all compounds of interest were eluted. The flow then was increased to 1 mL/min and diverted to waste as a wash step. At 5.9 minutes, the flow decreased back to 100 µL/min. The total chromatographic run time for each sample was 6.0 minutes, and typical elution times for 25(OH)D 2 , 25(OH)D 3 , and ∆ 9 -THC-D 3 were 2.90, 2.89, and 2.93 minutes, respectively. The mass detector acquisition and tune settings are shown in ❚Table 1❚ and ❚Table 2❚. Electrospray ionization was performed in the positive mode. 
Method Validation
The precision, linearity, and limit of detection were evaluated to assess the performance characteristics of the assay. Interassay precision was assessed for 25(OH)D 2 and 25(OH)D 3 using a minimum of 20 low and high control samples for each analyte extracted in multiple runs per day. Intraassay precision used the same control samples with a minimum of 20 times within a run. Assay linearity was determined by serially diluting spiked serum samples with saline and comparing results with theoretical values. Twenty replicate measurements of the saline blank were used to determine the lower limit of detection, defined as the mean of the negative sample plus 2 SD. The biological limit of detection was established by using the lower limit of detection plus 2 SD obtained from a saline-diluted serum pool to achieve 3 low concentrations for 25(OH)D 2 and 25(OH)D 3 using 20 replicate experiments. Functional sensitivities were calculated based on the lowest analyte concentrations of the diluted serum pools with interassay coefficients of variation (CVs) of less than 20%. Analytical recovery was determined by adding the vitamin D analytes to serum at 3 concentrations (5.0, 15.0, and 100.0 ng/mL) and analyzing the specimens.
Method Comparison and Reference Intervals
The LC-MS/MS method was compared with the DiaSorin RIA (Stillwater, MN) by using aliquots from 57 patient serum samples. Deming regression was used for statistical comparison of the methods. Serum samples from 110 healthy individuals also were assayed to assess reference intervals for 25(OH)D 2 and 25(OH)D 3 and to verify the reference interval used with the RIA method. Approval for these studies was obtained from the University of Washington Institutional Review Board (Seattle). Volunteers answered a questionnaire about race, age, sex, medications, and exogenous vitamin D intake. Reference interval data were analyzed according to the National Committee for Clinical Laboratory Standards guideline for determining reference values. 17 Data points were placed in decreasing order and evaluated to determine outliers. The central 95% of the data were taken as the reference interval for each analyte.
Serum calcium and plasma parathyroid hormone (PTH) levels were measured for comparison with total 25(OH)D levels and with abnormal levels used as exclusion criteria for the reference interval study. Serum calcium and plasma PTH levels were measured on the Beckman LX20 (Beckman Coulter, Fullerton, CA) and Roche Elecsys 1010 (Roche Diagnostics, Mannheim, Germany), respectively. Plasma and serum specimens were separated and stored at -70°C until analysis.
Results
Examples of extracted ion chromatograms for 25(OH)D 2 , 25(OH)D 3 , and ∆ 9 -THC-D 3 are shown in ❚Figure 1❚. Ion suppression was tested by HPLC analysis of an extracted serum specimen along with postcolumn infusion of 25(OH)D 2 , 25(OH)D 3 , and ∆ 9 -THC-D 3 . Minimal matrix ion suppression was compensated for by use of a coeluting internal standard when analyte/internal standard ratios were used for quantitation.
The performance characteristics of the LC-MS/MS method are given in ❚Table 3❚. Interassay CVs were 11.4% to 11.5% and 7.7% to 9.8% and intra-assay CVs were 6.9% to 8.8% and 6.0% to 8. 18, 19 To assess correlation of the LC-MS/MS method with an RIA, 57 patient serum specimens were analyzed by both methods. As shown in ❚Figure 2❚, Deming regression analysis showed that the methods were comparable and yielded a slope of 0.97 (95% confidence interval, 0.88-1.05) and y-intercept of -1.74 ng/mL. It should be noted that only total vitamin D levels were evaluated owing to the cross-reactivity properties of the RIA.
To establish our reference range, serum samples from 116 healthy volunteers (age range, 22-65 years) were analyzed for calcium, PTH, 25(OH)D 2 , and 25(OH)D 3 levels. The serum calcium levels were normal in all (mean ± SD, 9.8 ± 0.4 mg/dL [2.45 ± 0.10 mmol/L]), but samples from 6 volunteers were excluded from the study owing to an elevated PTH level. Their mean serum PTH level was 39 ± 12 pg/mL (4.1 ± 1. Internal standards typically are structurally analogous to the analytes of interest in chromatographic methods. However, in most cases, finding an appropriate internal standard can be cumbersome and expensive. For example, stable isotopes of vitamin D require lengthy synthesis, and, at the [22] [23] [24] [25] Much of the current literature on 25(OH)D levels recommends cutoff values between 20 and 32 ng/mL (50-80 nmol/L) to diagnose vitamin D deficiency. [26] [27] [28] At these higher levels, secondary hyperparathyroidism subsides, bone mineral density increases substantially, optimal intestinal calcium absorption is observed, and nonspecific musculoskeletal chronic pain can subside. 3, [22] [23] [24] [25] As awareness of vitamin D deficiency increases, more laboratories are increasing levels used to define desirable and normal levels of total 25(OH)D. Ideally, it is advantageous to have established guidelines for 25(OH)D levels that correspond to disease states owing to the large annual fluctuations in vitamin D levels in many people. Although serum levels of 25(OH)D ideally are suited to best represent a patient's true vitamin D status, measurement of 1,25-dihydroxyvitamin D also is clinically useful to assess alterations in various disorders of calcium metabolism. An LC-MS/MS assay is in development to detect 1,25-dihydroxyvitamin D at picomolar concentrations.
Results from our reference interval study advocate use of 25(OH)D guidelines based on disease states vs reference intervals based on a seemingly healthy population. It is critical to note that these studies were conducted in the middle of winter in Seattle (47° latitude). A minimum energy of 20 kJ/cm 2 is needed to produce cutaneous vitamin D 3 , and, during the winter months in US states above 40° latitude, that exposure level is not achieved, even during seemingly sunny conditions. 29, 30 Thus, our patient population was theoretically in its lowest annual vitamin D status. Extremely low levels were achieved in the population of healthy volunteers, with the calculated reference interval mean for total 25(OH)D (19.3 ng/mL [48 nmol/L]) only slightly higher than our current desirable level (>15 ng/mL [>37 nmol/L]). However, it would be unwise to decrease our present guidelines owing to the numerous studies documenting impaired endocrine function and increased risk of disease to patients at low circulating 25(OH)D levels. More study is warranted to establish reference intervals that truly represent the healthy population in the Northwest.
We have developed a rapid, sensitive LC-MS/MS method for specifically measuring serum levels of 25(OH)D 2 and 25(OH)D 3 at nanomolar concentrations using a novel internal standard. Owing to lower cost and shorter analysis times, this method is suitable not only for routine clinical measurement of serum 25(OH)D levels but also for multicenter clinical trials. 
